Precision in action: Targeted strategies across the cancer care continuum

Precision oncology is changing how clinicians approach cancer—from intervening earlier in high-risk disease to overcoming treatment resistance and targeting actionable molecular drivers.^1-4 Eli Lilly oncology developments build on these principles.

Primarily, long-term monarchE findings show that precisely targeting high-risk early breast cancer (EBC) with abemaciclib (Yulareb) delivers benefit that outlasts the two-year treatment course itself.¹ That same precision extends to different malignancies with pirtobrutinib’s (Jaypirca) local approval, providing an option in addressing treatment resistance in chronic lymphocytic leukemia (CLL) while focus on RET-directed approach gives light to an upcoming treatment modality.^2-4  

To better understand how these molecules help patients across their cancer journey, access the infographic below.